OWD
BMRN icon

Osborn Williams & Donohoe’s BioMarin Pharmaceuticals BMRN Stock Holding History

Osborn Williams & Donohoe’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,872
Closed -$246K – 308
2019
Q2 		$246K Sell
2,872
-2,278
-44% -$195K 0.03% 291
2019
Q1 		$457K Buy
+5,150
New +$477K 0.05% 251

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Osborn Williams & Donohoe's BMRN Position: Q3 2019 in Review

Osborn Williams & Donohoe sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 2,872 shares — an estimated $246K sold.

Osborn Williams & Donohoe first reported a position in BMRN in Q1 2019 and held it in 2 quarters. The position peaked at $457K in Q1 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Osborn Williams & Donohoe reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 2,872 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $246K.
  • Osborn Williams & Donohoe first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Osborn Williams & Donohoe's BioMarin Pharmaceuticals position peaked at $457K in Q1 2019.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q3 2019, filed 16 Oct 2019.